Agenda

View Full Calendar

Nieuwsbrief




Registration for our 2010 conference has started. Early bird tickets now available!

Banner
Artikelen

Over het algemeen worden psychedelische drugs als LSD en MDMA door de meeste mensen niet geassocieerd met het laboratorium, maar dat lijkt steeds meer te veranderen. Voor het eerst in veertig jaar wordt er weer aandacht besteed aan het medische potentieel van zulke substanties, en de eerste clinical trials van onderzoek naar bijvoorbeeld MDMA en PTSD zijn veelbelovend. In Amerika en Zwitserland komen er onderzoeken aan die aandacht besteden aan het effect van LSD en psilocibine bij patienten met (terminale) kanker die last hebben van angsten en depressies. De New Scientist, een vooraanstaand medisch tijdschrift uit Amerika, heeft er een uitgebreid en interessant artikel over geschreven, dat je hier in z'n geheel kunt lezen!

Abstract


Case reports indicate that psychiatrists administered ±3,4-methylenedioxymethamphetamine (MDMA) as a catalyst to psychotherapy before recreational use of MDMA as ‘Ecstasy’ resulted in its criminalization in 1985. Over two decades later, this study is the first completed clinical trial evaluating MDMA as a therapeutic adjunct. Twenty patients with chronic posttraumatic stress disorder, refractory to both psychotherapy and psychopharmacology, were randomly assigned to psychotherapy with concomitant active drug (n = 12) or inactive placebo (n = 8) administered during two 8-h experimental psychotherapy sessions. Both groups received preparatory and follow-up non-drug psychotherapy. The primary outcome measure was the Clinician-Administered PTSD Scale, administered at baseline, 4 days after each experimental session, and 2 months after the second session. Neurocognitive testing, blood pressure, and temperature monitoring were performed. After 2-month follow-up, placebo subjects were offered the option to re-enroll in the experimental procedure with open-label MDMA. Decrease in Clinician-Administered PTSD Scale scores from baseline was significantly greater for the group that received MDMA than for the placebo group at all three time points after baseline. The rate of clinical response was 10/12 (83%) in the active treatment group versus 2/8 (25%) in the placebo group. There were no drug-related serious adverse events, adverse neurocognitive effects or clinically significant blood pressure increases. MDMA-assisted psychotherapy can be administered to posttraumatic stress disorder patients without evidence of harm, and it may be useful in patients refractory to other treatments.

Bron: http://jop.sagepub.com/content/early/2010/07/14/0269881110378371

Ayahuasca is a psychoactive beverage used for magico-religious purposes in the Amazon. Recently, Brazilian syncretic churches have helped spread the ritual use of ayahuasca abroad. This trend has raised concerns that regular use of this N,N-dimethyltryptamine-containing tea may lead to the medical and psychosocial problems typically associated with drugs of abuse. Here we assess potential drug abuse- related problems in regular ayahuasca users. Addiction severity was assessed using the Addiction Severity Index (ASI), and history of alcohol and illicit drug use was recorded.

In Study 1, jungle-based ayahuasca users (n = 56) were compared vs. rural controls (n = 56). In Study 2, urban-based ayahuasca users (n = 71) were compared vs. urban controls (n = 59). Follow-up studies were conducted 1 year later. In both studies, ayahuasca users showed significantly lower scores than controls on the ASI Alcohol Use, and Psychiatric Status subscales. The jungle-based ayahuasca-usersshowed a significantly higher frequency of previous illicit drug use but this had ceased at the time of examination, except for cannabis. At follow-up, abstinence from illicit drug use was maintained in both groups except for cannabis in Study 1. However, differences on ASI scores were still significant in the jungle-based group but not in the urban group. Despite continuing ayahuasca use, a time-dependent worsening was only observed in one subscale (Family/Social relationships) in Study 2. Overall, the ritual use of ayahuasca, as assessed with the ASI in currently active users, does not appear to be associated with the deleterious psychosocial effects typically caused by other drugs of abuse.

Authors: Josep Maria Fábregasa, Débora González a, Sabela Fondevilab, Marta Cutchet, Xavier Fernández, Paulo César Ribeiro Barbosa, Miguel Ángel Alcázar-Córcolese, Manel J. Barbanoj, Jordi Riba, José Carlos Bouso.

Bron: http://bialabate.net het hele artikel kun je hier lezen.

This research focuses on the events leading to the 1968 U.S. federal prohibition of psilocybin. It is a study of duelling moral entrepreneurs-Timothy Leary and Richard Alpert vs. the Harvard University Administration. The goal is to show how the primary active compound in an ostensibly harmless fungus (the psilocybin mushroom) became controversial in less than a decade.

Methods: We used books, newspapers, magazine articles and previously unpublished materials (including documents from the Harvard Archives) to analyze Leary and Alpert's lives and careers through the early 1970s.

Results: The prohibition of psilocybin in the U.S. was largely a product of Leary and Alpert's involvement in the "Harvard drug scandal" and their transformation from Harvard professors to countercultural icons. They tested the substance on a variety of human subjects and in doing so piqued the interest of Harvard undergraduates while drawing condemnation from other faculty and Harvard administrators. This case is theoretically interesting because unlike most illegal drugs, psilocybin was never linked to a threatening minority group, but to some of the nation's most privileged youth.

Conclusion: The Harvard administrators were not really moral entrepreneurs but Leary and Alpert clearly were. Although they were far from being prohibitionists, they were self-righteous crusaders on different but equally holy missions for the good of young and minority Americans. Ironically, due to their successes the possession of psilocybin was criminalized under United States federal law in 1968 (Pub. L. No. 90-639, Stat. 1361 1968 and Boire, 2002). This case study demonstrates that crusaders can be successful in changing culture even when laws are passed in futile attempts to control their behaviour, just as Leary predicted.

Authors: Colin Warka, John F. Galliherb

 

Abstract
The elimination of subjectivity through brain research and the replacement of so-called ‘folk psychology’ by a neuroscientifically enlightened worldview and self-conception has been both hoped for and feared. But this cultural revolution is still pending. Based on nine months of fieldwork on the revival of hallucinogen research since the ‘Decade of the Brain,’ this paper examines how subjective experience appears as epistemic object and practical problem in a psychopharmacological laboratory. In the quest for neural correlates of (drug-induced altered states of) consciousness, introspective accounts of test subjects play a crucial role in neuroimaging studies. Firsthand knowledge of the drugs’ flamboyant effects provides researchers with a personal knowledge not communicated in scientific publications, but key to the conduct of their experiments. In many cases, the ‘psychedelic experience’ draws scientists into the field and continues to inspire their self-image and way of life. By exploring these domains the paper points to a persistence of the subjective in contemporary neuropsychopharmacology.

Bron: History of Human Sciences, Volume 23, Number 1, 2010, pp. 37-57

by N. Langlitz



|

Do entheogen-induced mystical experiences boost the immune system?
Psychedelics, peak experiences, and wellness


by Thomas B. Roberts
Thomas B. Roberts PhD is a Professor of Educational Psychology at Northern Illinois University, DeKaIb, IL (USA), where he has taught courses on transpersonal, mind-body, psychedelic, and consciousness topics.

Abstract. Daily events that boost the immune system (as indicated by levels of salivary immunoglobulin A), some instances of spontaneous remission, and mystical experiences seem to share a similar cluster of thoughts, feelings, moods, perceptions, and behaviors. Entheogens – psychedelic drugs used in a religious context – can also produce mystical experiences (peak experiences, states of unitive consciousness, intense primary religious experiences) with the same cluster of effects. When this happens, is it also possible that such entheogen-induced mystical experiences strengthen the immune system? Might spontaneous remissions occur more frequently under such conditions? This article advances the so called "Emxis hypothesis" – that entheogen-induced mystical experiences influence the immune system.

Combined observations from biology, medicine, religion, psychology, and psychotherapy point to the possibility of a fascinating relationship among entheogens (psychoactive plants and chemicals used in a religious context), mystical experiences, and the immune system – that entheogen-induced mystical experiences may strengthen the immune system. I call this proposition the "Emxis hypothesis – emxis" being a partial acronym of sorts for "Entheogen-induced Mystical eXperiences Influence the immune System."

Bron: Advances in Mind-Body Medicine, 15 (1999) : 139-147

<< Start < Vorige 1 2 3 Volgende > Einde >>
JPAGE_CURRENT_OF_TOTAL